狠狠综合久久AV一区二区 ,中文字幕乱码无码人妻系列蜜桃,国产精品毛片无遮挡高清

美國(guó)Seracare百日咳桿菌Bordela Pertussis

廣州健侖生物科技有限公司

廣州健侖長(zhǎng)期供應(yīng)各種生物原料，主要代理品牌：美國(guó)Seracare、西班牙Certest、美國(guó)Fuller等等。

主要產(chǎn)品包括各種標(biāo)準(zhǔn)品、陽性對(duì)照品、單克隆抗原抗體。

其中常見的有：弓形蟲病、西尼羅河病毒、類風(fēng)濕因子、瘧疾、麻疹、萊姆病、百日咳桿菌、大腸桿菌、鼠傷寒沙門氏菌、李斯特菌等陽性對(duì)照品。

美國(guó)Seracare百日咳桿菌Bordela Pertussis

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【Seracare產(chǎn)品介紹】

編號(hào)	英文名稱	中文名稱
JL-FA-01	Amebiasis (AME)	阿米巴病
JL-FA-02	Allergens, Rast scores	過敏原，放射性過敏原吸收實(shí)驗(yàn)。指對(duì)特定的人群引起免疫反應(yīng)或者過敏反應(yīng)的食品中的蛋白質(zhì)
JL-FA-03	Allergens, Rast scores negative	過敏原，放射性過敏原吸收實(shí)驗(yàn)陰性
JL-FA-04	Anti-cyclic citrullinated peptide Antibody (CCP) Arthritis	抗環(huán)瓜氨酸肽抗體
JL-FA-05	ASCA Saccharomyces Cerevi	人抗釀酒酵母抗體（ASCA）
JL-FA-06	Aspergillis	麴菌病
JL-FA-07	Beta 2 Glycoprotein	β2糖蛋白
JL-FA-08	Beta 2 Glycoprotein IgM	β2糖蛋白 IGM
JL-FA-09	Bordela Pertussis	百日咳桿菌
JL-FA-10	Bordela Pertussis IgM	百日咳桿菌 IGM
JL-FA-11	C-ANCA	C-抗中性粒細(xì)胞胞漿抗體（ANCA)
JL-FA-12	Cardiolipin	心肌磷脂
JL-FA-13	Cardiolipin IgA	心肌磷脂 IGA
JL-FA-14	Cardiolipin IgG	心肌磷脂 IGG
JL-FA-15	Cardiolipin IgM	心肌磷脂 IGM
JL-FA-16	Cerebral Spinal Fluid	腦脊髓液
JL-FA-17	Chagas	恰加斯病/南美錐蟲
JL-FA-18	Chlamydia	衣原體
JL-FA-19	Chlamydia IgA	衣原體IGA
JL-FA-20	Chlamydia IgG	衣原體IGG
JL-FA-21	Chlamydia IgM	衣原體IGM
JL-FA-22	Chlamydia Neg	衣原體陰性
JL-FA-23	Clotting Factor C3	凝固因子C3
JL-FA-24	Clotting Factor C4	凝固因子C4
JL-FA-25	Coccidiodes	球孢菌
JL-FA-26	Cytomegalovirus (CMV) Neg	巨細(xì)胞病毒抗體陰性
JL-FA-27	CMV IgG	巨細(xì)胞病毒 IGG陽性
JL-FA-28	CMV IgM VCA	巨細(xì)胞病毒 IGM 陽性
JL-FA-29	C-Reactive Protein (CRP)	C-反應(yīng)蛋白質(zhì)
JL-FA-30	Dengue Fever	登革熱
JL-FA-31	Dengue Fever IgM	登革熱 IGM
JL-FA-32	DS (Double Stranded) DNA	雙鏈脫氧核糖核酸
JL-FA-33	EBNA (Epstein-Barr nuclear antigen) IgG	EB病毒核抗原 IGG
JL-FA-34	EBNA (Epstein-Barr nuclear antigen) IgM	EB病毒核抗原 IGM
JL-FA-35	Epstein Barr Virus (EBV) Negative Plasma	EB病毒陰性血漿
JL-FA-36	Epstein Barr Virus (EBV) EA IgM	EB病毒早期抗原 IGM
JL-FA-37	Epstein Barr Virus (EBV) VCA IgM	EB病毒殼蛋白 IGM
JL-FA-38	Epstein Barr Virus (EBV) EA IgG	EB病毒早期抗原 IGG
JL-FA-39	EMA (Endomysial Antibodies)	肌內(nèi)膜
JL-FA-40	Gliadin	麩蛋白,麥醇溶蛋白,麥膠蛋白
JL-FA-41	Gliadin IgG	麥醇溶蛋白 IGG
JL-FA-42	Gliadin IgA	麥醇溶蛋白 IGA
JL-FA-43	Glomerular Basement Membrane (GBMA)	腎小球基底膜病
JL-FA-44	Helicobacter pylori IgA	幽門螺旋桿菌IGA
JL-FA-45	Helicobacter pylori IgG	幽門螺旋桿菌IGG
JL-FA-46	Helicobacter pylori IgM	幽門螺旋桿菌IGM
JL-FA-47	Helicobacter pylori Negative	幽門螺旋桿菌陰性
JL-FA-48	Helicobacter pylori Positive Plasma	幽門螺旋桿菌陰性血漿
JL-FA-49	Hepatitis A Virus (HAV) Pos. Plasma	甲型肝炎病毒陽性血漿
JL-FA-50	Hepatitis A Virus (HAV) IgM	甲型肝炎病毒IGM
JL-FA-51	Hepatitis B Core (HBc) IgG	乙型肝炎病毒核心 IGG
JL-FA-52	Hepatitis B Core (HBc) IgM	乙型肝炎病毒核心 IGM
JL-FA-53	Anti Hbe (Antibody to HBV antigen)	乙肝抗體
JL-FA-54	Hepatitis Delta Virus	丁型肝炎病毒
JL-FA-55	HBeAg (HBV e antigen)	乙肝 E抗原
JL-FA-56	anti-HBs (HBV surface antibody)	乙肝表面抗體
JL-FA-57	Hepatitis B (HBsAg) "Chronic"	乙型肝炎（乙肝表面抗原）“慢性病
JL-FA-58	HBsAg (HBV surface antigen) Serum	乙肝表面抗原血清
JL-FA-59	HBsAg (AD)	乙肝表面抗原（AD）
JL-FA-60	HBsAg (AY)	乙肝表面抗原（AY）
JL-FA-61	HBV Positive Plasma	乙肝陽性血漿
JL-FA-62	HBV DNA Plasma	乙肝DNA血漿
JL-FA-63	HBV DNA Serum	乙肝DNA血清
JL-FA-64	HBV DNA type A	A型乙肝DNA
JL-FA-65	HBV DNA type B	B型乙肝DNA
JL-FA-66	HBV DNA type C	C型乙肝DNA
JL-FA-67	HBV DNA type D	D型乙肝DNA
JL-FA-68	HBV DNA type E	E型乙肝DNA
JL-FA-69	HBV DNA type F	F型乙肝DNA
JL-FA-70	HBV Antibody HCV Antibody Plasma CO-INFECTED	乙肝和丙肝聯(lián)合感染血漿
JL-FA-71	HCV (Hepatitis C Virus) Antibody	丙型肝炎抗體
JL-FA-72	HCV Core Antigen Positive	丙肝核心抗原陽性
JL-FA-73	HCV RNA PLASMA Genotype 1	基因1型丙肝RNA 血漿
JL-FA-74	HCV RNA PLASMA Genotype 2	基因2型丙肝RNA 血漿
JL-FA-75	HCV RNA PLASMA Genotype 3	基因3型丙肝RNA 血漿
JL-FA-76	HCV RNA PLASMA Genotype 4	基因4型丙肝RNA 血漿
JL-FA-77	HCV RNA PLASMA Genotype 5	基因5型丙肝RNA 血漿
JL-FA-78	HCV RNA PLASMA Genotype 6	基因6型丙肝RNA 血漿
JL-FA-79	HCV Riba single band	丙肝免疫印跡單波段
JL-FA-80	HCV RIBA Pos. (multiple bands)	丙肝免疫印跡陽性多波段
JL-FA-81	HCV Negative	丙肝陰性
JL-FA-82	HCV RNA Pos (quantitative)	丙肝RNA陽性（定量）
JL-FA-83	Hepatitis E	戊型肝炎
JL-FA-84	Herpes Simplex Virus (HSV)1/2 Positive Plasma	單純性皰疹病毒1/2陽性血漿
JL-FA-85	Herpes Simplex Virus (HSV) 1 Negative Plasma	單純性皰疹病毒1 陰性血漿
JL-FA-86	Herpes Simplex Virus (HSV) 1 IgG	單純性皰疹病毒1 IGG
JL-FA-87	Herpes Simplex Virus (HSV 1) IgM	單純性皰疹病毒1 IGM
JL-FA-88	Herpes Simplex Virus (HSV) 2 IgG	單純性皰疹病毒2 IGG
JL-FA-89	Herpes Simplex Virus (HSV) 2 IgM	單純性皰疹病毒2 IGG
JL-FA-90	Histone	組蛋白
JL-FA-91	Human Anti Mouse Ab (HAMA)	人抗鼠抗體
JL-FA-92	Human immunodeficiency virus (HIV) 1 Neg	HIV I 陰性
JL-FA-93	anti Human immunodeficiency virus (HIV) 1 Plasma	抗HIV I 血漿
JL-FA-94	anti Human immunodeficiency virus (HIV) 1 Serum	抗HIV I 血清
JL-FA-95	anti Human immunodeficiency virus (HIV) 2 Western Blot Tested	抗HIV 2 免疫印跡
JL-FA-96	anti Human immunodeficiency virus (HIV) 1/2 2 HIV (+)	抗HIV 1/2 2 HIV陽性
JL-FA-97	Human immunodeficiency virus (HIV) Ag	HIV抗原
JL-FA-98	HIV RNA (quantitative) Plasma	HIV RNA 定量血漿
JL-FA-99	HIV RNA (quantitative) Serum	HIV RNA 定量血清
JL-FA-100	HIV1 Subtype A	HIV1 亞型A
JL-FA-101	HIV1 Subtype B	HIV1 亞型B
JL-FA-102	HIV1 Subtype C	HIV1 亞型C
JL-FA-103	HIV1 Subtype D	HIV1 亞型D
JL-FA-104	HIV1 Subtype E	HIV1 亞型E
JL-FA-105	HIV1 Subtype F	HIV1 亞型F
JL-FA-106	HIV1 Subtype G	HIV1 亞型G
JL-FA-107	HIV1 Subtype H	HIV1 亞型H
JL-FA-108	HIV1 Subtype J	HIV1 亞型J
JL-FA-109	HIV1 Subtype K	HIV1 亞型K
JL-FA-110	HIV1 Group O	HIV1 亞型O
JL-FA-111	Human immunodeficiency virus (HIV) 2 Antibody Plasma	HIV 2 抗體血漿
JL-FA-112	Human immunodeficiency virus (HIV) 2 Antibody Serum	HIV 2 抗體血清
JL-FA-113	HPV (Human Papiloma Virus) Negative	人乳狀瘤病毒HPV陰性
JL-FA-114	HPV (Human Papiloma Virus) Positive	人乳狀瘤病毒HPV陽性
JL-FA-115	Human immunodeficiency virus (HIV) Antibody HCV Antibody Plasma COINFECTED	HIV 抗體 HCV
JL-FA-116	Human T-cell Lymphotropic Virus (HTLV) I/II	人嗜T淋巴細(xì)胞病毒(HTLV) I/II
JL-FA-117	Human T-cell Lymphotropic Virus (HTLV) I	人嗜T淋巴細(xì)胞病毒(HTLV) I
JL-FA-118	Human T-cell Lymphotropic Virus (HTLV) II	人嗜T淋巴細(xì)胞病毒(HTLV) II
JL-FA-119	Jo-1	多發(fā)性肌炎抗原JO-1
JL-FA-120	IgE < 5,000 Ku/L	IgE < 5,000 Ku/L
JL-FA-121	Legionella	軍團(tuán)桿菌屬
JL-FA-122	Leptospira	軍團(tuán)桿菌屬
JL-FA-123	Lyme Disease	萊姆(氏)病:蜱傳播的全身性疾病,常在夏季發(fā)生
JL-FA-124	Lyme IgG	萊姆(氏)病 IGG
JL-FA-125	Lyme IgM	萊姆(氏)病 IGM
JL-FA-126	Lyme Disease Neg	萊姆(氏)病陰性
JL-FA-127	Malaria	瘧疾
JL-FA-128	Mononucleosis (infectious)	單核細(xì)胞增多癥（有傳染性的）
JL-FA-129	Mononucleosis Negative	單核細(xì)胞增多癥陰性
JL-FA-130	Measles Negative	麻疹陰性
JL-FA-131	Measles IgG	麻疹 IGG
JL-FA-132	Measles IgM	麻疹 IGM
JL-FA-133	Microsomal Anti-thyroid peroxidase antibody (TPO) Positive Plasma Standard Titer (typically 1,000-3,000 IU/mL)	微粒體抗甲狀腺過氧化物酶抗體
JL-FA-134	Microsomal Anti-thyroid peroxidase antibody (TPO) Negative Plasma	微粒體抗甲狀腺過氧化物酶抗體
JL-FA-135	Anti-mitochondrial antibody (AMA)	抗線粒體抗體
JL-FA-136	Multiple Sclerosis	多發(fā)性硬化癥
JL-FA-137	Mumps IgG	流行性腮腺炎 IGG
JL-FA-138	Mumps Ab IgM	流行性腮腺炎抗體 IGM
JL-FA-139	Mumps Antibody Negative Plasma	流行性腮腺炎抗體陰性血漿
JL-FA-140	Mumps Antibody Negative Serum	流行性腮腺炎抗體陰性血清
JL-FA-141	Myeloma Plasma	骨髓瘤血漿
JL-FA-142	Myeloma IgA	骨髓瘤IGA
JL-FA-143	Myeloma IgE	骨髓瘤IGE
JL-FA-144	Myeloma IgG	骨髓瘤IGG
JL-FA-145	Myeloma IgM	骨髓瘤IGM
JL-FA-146	Mycoplasma	支原體
JL-FA-147	Mycoplasma Negative	支原體陰性
JL-FA-148	Mycoplasma IgG	支原體IGG
JL-FA-149	Mycoplasma IgM	支原體IGM
JL-FA-150	Mycoplasma PCR	支原體PCR
JL-FA-151	Normal Human Plasma	正常人血漿
JL-FA-152	Normal Human Serum	正常人血清
JL-FA-153	Nuclear Antibody Centromere	核抗體著絲粒
JL-FA-154	Nuclear Antibody, Speckled ANA	核抗體，斑點(diǎn)抗核抗體
JL-FA-155	Nuclear Antibody, Nucleolar ANA	核抗體,核仁抗核抗體
JL-FA-156	Nuclear Antibody, Homogeneous ANA	核抗體，同質(zhì)抗核抗體
JL-FA-157	Nuclear Antiobody, Speckled. (ANA) Negative	核抗體，斑點(diǎn)?？购丝贵w陰性
JL-FA-158	P-ANCA (associated neutrophil cytoplasmic antibodies)	相關(guān)的嗜中性粒細(xì)胞胞漿抗體
JL-FA-159	Parietal Cell Antibody (PCA)	胃)壁細(xì)胞抗體
JL-FA-160	Parvo positive plasma	細(xì)小病毒陽性血漿
JL-FA-161	Parvo IgM	細(xì)小病毒 IGM
JL-FA-162	Parvo IgG	細(xì)小病毒 IGG
JL-FA-163	Parvo Negative Plasma	細(xì)小病毒陰性血漿
JL-FA-164	Parvo DNA positive	細(xì)小病毒 DNA 陽性
JL-FA-165	Phospholipid Positive Plasma	磷脂陽性血漿
JL-FA-166	Prothrombin	凝血酶原,凝血因子
JL-FA-167	Rheumatoid Factor (RF) <1000 IU/mL	類風(fēng)濕因子<1000 IU/mL
JL-FA-168	Rheumatoid Factor (RF) 1001-2000 IU/mL	類風(fēng)濕因子1001-2000 IU/mL
JL-FA-169	Rheumatoid Factor (RF) 2001-4000 IU/mL	類風(fēng)濕因子 2001-4000 IU/mL
JL-FA-170	Rheumatoid Factor (RF) 4001-5000 IU/mL	類風(fēng)濕因子 4001-5000 IU/mL
JL-FA-171	Rheumatoid Factor (RF) >5000 IU/mL	類風(fēng)濕因子>5000 IU/mL
JL-FA-172	Ribonucleoprotein (RNP) Positive	核糖核蛋白陽性
JL-FA-173	Rubella Chimeric	風(fēng)疹
JL-FA-174	Rubella Negative	風(fēng)疹陰性
JL-FA-175	Rubella IgG	風(fēng)疹I(lǐng)GG
JL-FA-176	Rubella IgM	風(fēng)疹I(lǐng)GM
JL-FA-177	Rubeola Negative Plasma	風(fēng)疹陰性血漿
JL-FA-178	Rubeola IgG	風(fēng)疹I(lǐng)GG
JL-FA-179	Scleroderma (Scl-70) Pos	膠原沉著病,硬皮病,硬皮癥陽性
JL-FA-180	Scleroderma (Scl-70) Negative	硬皮病陰性
JL-FA-181	Sickle Cell Fresh Whole Blood	鐮刀形紅細(xì)胞新鮮全血
JL-FA-182	Smith (SM)	抗Smith抗體陽性血清（SLE的特征性抗體）
JL-FA-183	SMITH RNP	抗RNP抗體陽性血清（SLE的特征性抗體）
JL-FA-184	Smooth Muscle (ASMA)	抗平滑肌抗體陽性血清
JL-FA-185	Sjogren syndrome antigen A (SSA) Positive	舍格倫綜合征或干燥綜合征抗原A 陽性
JL-FA-186	Sjogren syndrome antigen B (SSB) Positive	舍格倫綜合征抗原B 陽性
JL-FA-187	Sjogren syndrome antigen B (SSB) Negative	舍格倫綜合征抗原B陰性
JL-FA-188	Streptolysin O Ab (ASO)	鏈球菌溶血素O抗體
JL-FA-189	Syphilis (RPR - Rapid Plasma Reagin) Positive Plasma	梅毒（梅毒-快速血漿反應(yīng)）陽性血漿
JL-FA-190	Syphilis (RPR - Rapid Plasma Reagin) Negative Plasma	梅毒（梅毒-快速血漿反應(yīng)）陰性血漿
JL-FA-191	Syphilis/ATA/T. pallidum IgG	梅毒ATA/T，蒼白球IGG
JL-FA-192	Syphilis/ATA/T. pallidum IgM	梅毒ATA/T，蒼白球IGM
JL-FA-193	Systemic Lupus Erythematosus (SLE) Positive	全身性紅斑狼瘡陽性
JL-FA-194	Systemic Lupus Erythematosus (SLE) Negative	全身性紅斑狼瘡陰性
JL-FA-195	TG/TPO Positive (Standard Titer 1,000 - 3000 IU/mL)	甲狀腺球蛋白/甲狀腺過氧化物酶陽性
JL-FA-196	TG/TPO Negative	甲狀腺球蛋白/甲狀腺過氧化物酶陰性
JL-FA-197	TTG (Tissue Transglutaminase)	組織轉(zhuǎn)谷氨酰胺酶
JL-FA-198	TTG (Tissue Transglutaminase) IgA	組織轉(zhuǎn)谷氨酰胺酶 IGA
JL-FA-199	ToRCH (Toxo, Rubella, CMV, HSV) Positive	優(yōu)生優(yōu)育（弓形蟲，風(fēng)疹，巨細(xì)胞，單胞）陽性
JL-FA-200	ToRCH (Toxo, Rubella, CMV, HSV) Negative	優(yōu)生優(yōu)育（弓形蟲，風(fēng)疹，巨細(xì)胞，單胞）陰性
JL-FA-201	Toxoplasmosis (Toxo)	弓形蟲病
JL-FA-202	Toxoplasmosis (Toxo) IgG	弓形蟲病IGG
JL-FA-203	Toxoplasmosis (Toxo) IgM	弓形蟲病IGM
JL-FA-204	Thyroglobulin (TG) Positive Plasma	甲狀腺球蛋白陽性血漿
JL-FA-205	Thyroglobulin (TG) Negative	甲狀腺球蛋白陰性
JL-FA-206	Varicella-Zoster Virus (VZV) Negative	水痘-帶狀皰疹病毒陰性
JL-FA-207	Varicella-Zoster Virus (VZV) IgG	水痘-帶狀皰疹病毒IGG
JL-FA-208	Varicella-Zoster Virus (VZV) IgM	水痘-帶狀皰疹病毒IGM
JL-FA-209	West Nile Virus (WNV)	西尼羅河腦炎病毒
JL-FA-210	West Nile Virus (WNV) IgM	西尼羅河腦炎病毒IGM

美國(guó)Seracare百日咳桿菌Bordela Pertussis

Zhenglong Gu及其同事分析了1000基因組項(xiàng)目的14個(gè)人群的1085個(gè)健康個(gè)體的整個(gè)線粒體基因組高質(zhì)量下一代測(cè)序數(shù)據(jù)。這些人的90%擁有至少一種異質(zhì)性，但是多數(shù)人的異質(zhì)性數(shù)量低。然而，所有這些人的19%攜帶了至少一種與疾病有關(guān)的異質(zhì)性。
這組作者說，隨著時(shí)間的推移，健康個(gè)體的可能有害的線粒體DNA變種的數(shù)量可能在一些細(xì)胞中增加，zui終達(dá)到了一個(gè)可能致病的臨界極限值，這強(qiáng)調(diào)了管理異質(zhì)性從而防止疾病進(jìn)程的重要性。
美國(guó)Salk研究所Juan Carlos Izpisua Belmonte實(shí)驗(yàn)室、華大基因(BGI)李英睿團(tuán)隊(duì)和中科院生物物理研究所劉光慧研究組合作，*利用全基因組測(cè)序(WGS)明確了現(xiàn)有疾病基因組靶向矯正工具的安全可靠性，并創(chuàng)建了效率遠(yuǎn)高于目前基因組靶向編輯技術(shù)的新型人類遺傳突變修復(fù)工具HDAdV，為開展以干細(xì)胞為基礎(chǔ)的基因治療提供了重要的理論依據(jù)。相關(guān)文章發(fā)表于2014年7月3日的《Cell Stem Cell》雜志上。
例子：血紅蛋白疾病(如鐮刀形細(xì)胞貧血癥和地中海貧血癥)的再生醫(yī)學(xué)治療策略
人誘導(dǎo)多能干細(xì)胞技術(shù)(iPSC)的出現(xiàn)，促進(jìn)了人類疾病基因組靶向矯正技術(shù)的快速發(fā)展。目前可用于人類疾病基因組靶向矯正的方法包括：核酶介導(dǎo)的DNA同源重組技術(shù)(如ZFN，TALEN及CRISPR/CAS9等)以及不依賴于核酶的大片段DNA同源重組技術(shù)(以第三代腺病毒載體HDAdV為代表)。經(jīng)遺傳修復(fù)的自體干細(xì)胞具有治療自身疾病的潛力，因此在個(gè)體醫(yī)學(xué)和再生醫(yī)學(xué)中具有廣闊的應(yīng)用前景。
劉光慧研究團(tuán)隊(duì)曾zui早利用HDAdV介導(dǎo)的基因組靶向編輯技術(shù)在兒童早衰癥患者iPSC中實(shí)現(xiàn)了對(duì)致病基因LMNA的靶向修復(fù)，從概念上證實(shí)了在病人細(xì)胞中原位矯正遺傳突變的可行性。他們繼而矯正了帕金森氏癥和范可尼貧血癥患者干細(xì)胞中的致病突變，為這些遺傳疾病的機(jī)理研究、藥物評(píng)價(jià)及個(gè)性化干細(xì)胞和基因治療奠定了基礎(chǔ)。
在該項(xiàng)研究中，研究人員*綜合利用HDAdV，TALEN和CRISPR三種不同的方法，對(duì)鐮刀形細(xì)胞貧血癥患者iPSC中發(fā)生突變的血紅蛋白基因(HBB)進(jìn)行靶向矯正。發(fā)現(xiàn)這三種基因矯正方法對(duì)于HBB基因具有類似的打靶效率。同時(shí)，全基因組深度測(cè)序結(jié)果顯示，TALEN和HDAdV在基因矯正過程中zui大限度地保持了病人基因組的完整性，從而提示了這些方法的安全可靠性。

美國(guó)Seracare百日咳桿菌Bordela Pertussis

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、食品安全、化妝品檢測(cè)、藥物濫用檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】廣州健侖生物科技有限公司
【市場(chǎng)部】楊永漢

【】
【騰訊】 2042552662
【公司地址】廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

Zhenglong Gu and colleagues analyzed high-quality, next-generation sequencing data for the entire mitochondrial genome of 1085 healthy individuals from 14 global populations of 1000 genome projects. 90% of these people have at least one heterogeneity, but most people have low levels of heterogeneity. However, 19% of all these people carry at least one disease-related heterogeneity.
Over time, the authors say, the number of potentially harmful mitochondrial DNA variants in healthy individuals may increase in some cells, culminating in a potentially pathogenic threshold, underscoring the management of heterogeneity and thus preventing The importance of the disease process.
The team of Juan Carlos Izpisua Belmonte, Salk Institute of USA, BGL Li Ying-Rui team and Liu Guang-hui Research Group, Institute of Biophysics, Chinese Academy of Sciences, for the first time made use of whole genome sequencing (WGS) to clarify the safety of existing disease genomic targeted remediation tools Reliability and create HDAdV, a novel human genetic mutation repair tool far more efficient than current genomic targeted editing techniques, providing an important theoretical basis for stem cell-based gene therapy. The article appeared in the July 3, 2014 issue of Cell Stem Cell.
Examples: Regenerative medical treatment strategies for hemoglobin diseases such as sickle cell anemia and thalassemia
The advent of human induced pluripotent stem cell technology (iPSC) has led to the rapid development of targeted therapies for human disease genomes. Currently available methods for target-directed genomic remediation of human diseases include ribozyme-mediated DNA homologous recombination techniques (eg, ZFN, TALEN and CRISPR / CAS9, etc.) and large fragment DNA-independent recombination techniques independent of ribozyme Third generation adenovirus vector HDAdV is representative). Genetically repaired autologous stem cells have the potential to treat their own diseases and therefore have broad applications in both individual medicine and regenerative medicine.
Liu Guanghui's team first used the HDAdV-mediated genome-targeted editing technique to target the pathogenic gene LMNA in the iPSC of patients with AP, and conceptually confirmed the feasibility of in situ correction of genetic mutations in patient cells . They then corrected pathogenic mutations in stem cells in patients with Parkinson's and Fanconi anemia and laid the foundation for mechanistic studies of these genetic diseases, drug evaluation, and personalized stem cell and gene therapy.
In this study, for the first time, the researchers used three different approaches, HDAdV, TALEN and CRISPR, to target-correct hemoglobin gene (HBB) mutations in iPSC in patients with sickle cell anemia. These three methods of gene correction were found to have similar targeting efficiency to HBB genes. At the same time, genome-wide deep sequencing showed that TALEN and HDAdV kept the integrity of the patient's genome during gene correction, which indicated the safety and reliability of these methods.